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Accurate identification of the transmitted virus and sequences evolving from it could be instrumental in
elucidating the transmission of human immunodeficiency virus type 1 (HIV-1) and in developing vaccines,
drugs, or microbicides to prevent infection. Here we describe an experimental approach to analyze HIV-1 env
genes as intact genetic units amplified from plasma virion RNA by single-genome amplification (SGA),
followed by direct sequencing of uncloned DNA amplicons. We show that this strategy precludes in vitro
artifacts caused by Taq-induced nucleotide substitutions and template switching, provides an accurate repre-
sentation of the env quasispecies in vivo, and has an overall error rate (including nucleotide misincorporation,
insertion, and deletion) of less than 8  105. Applying this method to the analysis of virus in plasma from
12 Zambian subjects from whom samples were obtained within 3 months of seroconversion, we show that
transmitted or early founder viruses can be identified and that molecular pathways and rates of early env
diversification can be defined. Specifically, we show that 8 of the 12 subjects were each infected by a single virus,
while 4 others acquired more than one virus; that the rate of virus evolution in one subject during an 80-day
period spanning seroconversion was 1.7  105 substitutions per site per day; and that evidence of strong
immunologic selection can be seen in Env and overlapping Rev sequences based on nonrandom accumulation
of nonsynonymous mutations. We also compared the results of the SGA approach with those of more-
conventional bulk PCR amplification methods performed on the same patient samples and found that the
latter is associated with excessive rates of Taq-induced recombination, nucleotide misincorporation, template
resampling, and cloning bias. These findings indicate that HIV-1 env genes, other viral genes, and even
full-length viral genomes responsible for productive clinical infection can be identified by SGA analysis of
plasma virus sampled at intervals typical in large-scale vaccine trials and that pathways of viral diversification
and immune escape can be determined accurately.
The transmission of human immunodeficiency virus type 1
(HIV-1) and the establishment of a productive infection are
complex biological processes, the precise mechanisms of which
remain to be elucidated. Because most HIV-1 transmissions
result from virus exposure at mucosal surfaces and because
there is a delay of approximately 1 to 3 weeks between virus
infection and the first detection of viral RNA (vRNA) in the
blood, it has been difficult to study the molecular details of
HIV-1 transmission and early diversification in humans (12, 30,
42). Initial studies of sexually acquired HIV-1 infection sug-
gested that virus populations in the acute phase are generally
genetically highly homogeneous, in contrast to the more het-
erogeneous viral populations found in chronic infections (4, 5,
52, 55–57). This observation, along with the observation that
new infections are almost always caused by CCR5-tropic vi-
ruses, suggested that HIV-1 infection is associated with a trans-
mission “bottleneck.” More-recent studies, however, have re-
ported heterogeneous virus populations near the time of
infection, including in samples from female sex workers from
Kenya and South Africa (11, 21, 22, 31) and in samples from
men who had sex with men in the United States (32), suggest-
ing that the routes and circumstances of infection may affect
the complexity of the transmitted virus (36). In particular,
sexually transmitted diseases, high viral loads in the donor, and
* Corresponding author. Mailing address: Department of Medicine,
University of Alabama at Birmingham, 720 20th Street South, Kaul
816, Birmingham, AL 35294. Phone: (205) 934-0412. Fax: (205) 934-
1580. E-mail: bhahn@uab.edu.
# These authors contributed equally to the work.
 Published ahead of print on 6 February 2008.
3952
particular routes of transmission increase the transmission ef-
ficiency of HIV-1 (28, 29, 48, 49) and may favor the transmis-
sion of multiple HIV-1 variants. Finally, it has been suggested
that the transmission of multiple variants is common, but that
homogenization of viral sequences occurs in the postinfection
period (15). Thus, while it is clear that HIV-1 infection can
result from the transmission of a single or more than one virus,
little else is known about the quantitative or qualitative fea-
tures of HIV-1 transmission, including the identities and phe-
notypic properties of the transmitted viruses.
Differing findings concerning the complexity of viruses in the
acute and early phases of HIV-1 infection likely result from a
combination of factors, including differences in study popula-
tions and associated risk behaviors; various clinical and labo-
ratory definitions of acute, early, and chronic infection; and
different experimental strategies used to analyze the genetic
complexity of the evolving viral quasispecies postinfection.
Chief among these are differences in the experimental designs
and the methodologies used. A common approach has been to
identify subjects within the first several months following in-
fection and to derive viral sequences by bulk or near-limiting-
dilution PCR amplification of proviral DNA or plasma RNA in
samples obtained from them, followed by cloning, sequencing,
and phylogenetic analysis (2, 4, 5, 9, 15, 21, 24, 31, 32, 36, 37,
57). In addition, acute infection cases have been analyzed by
using the heteroduplex tracking assay (HTA) (4, 15, 21, 31, 32).
While these approaches provide a first approximation of the
complexity of transmitted virus(es), they have significant limi-
tations. HTA, for example, interrogates only a fraction of the
gene of interest and does not provide sequence information (4,
15, 21, 31, 32). Consequently, HTA allows for only qualitative
inferences regarding the genetic complexity of virus popula-
tions. Bulk and near-endpoint PCR followed by cloning and
sequencing are compromised by Taq polymerase-mediated
template switching, which generates recombinants in vitro that
do not exist in vivo (6, 26, 35, 43, 54); the introduction of Taq
polymerase errors into cloned products (27); and nonpropor-
tional representation of target sequences due to template re-
sampling (44, 45) or unequal template amplification and clon-
ing (20, 27). Verified endpoint titration of viral nucleic acids
eliminates PCR-induced recombination and ensures the pro-
portional representation of target sequences (43), but if the
amplicon is molecularly cloned prior to sequencing (as is gen-
erally the case), it will contain Taq-induced nucleotide misin-
corporations (27).
In this study, we sought to develop an experimental strategy
that would allow us to amplify and sequence complete HIV-1
env genes from virion RNA in the plasma of infected individ-
uals while avoiding methodological artifacts inherent in previ-
ously used approaches. To this end, we adapted methods de-
scribed by Palmer and colleagues, who used single-genome
sequencing of uncloned pro-pol amplicons to identify geneti-
cally linked drug resistance mutations in plasma-derived virus
(27). The newly developed methods were applied to charac-
terize the evolving quasispecies in a cohort of heterosexual
Zambian subjects with acute or early HIV-1 clade C (or other)
infections who were screened at 3-month intervals for evidence
of incident infections. We also compared the results obtained
by single-genome amplification (SGA)-direct sequencing with
those obtained by more-conventional bulk PCR cloning and
sequencing methods on the same clinical specimens and de-
veloped methods for evaluating the sample misidentification
and cross-contamination that invariably occur in the setting of
a large field trial. Our results define an effective experimental
strategy for the molecular analysis of the transmission of
HIV-1 and its early evolution in cohorts with differing risk
behaviors and in vaccine trials where the identification of
transmitted viruses and molecular pathways of virus immune
escape can be instrumental in assessing vaccine efficacy or
failure.
MATERIALS AND METHODS
Subjects. The 12 subjects whose infections are characterized in this study were
enrolled in a cohort of heterosexual couples with discordant HIV infection status
(where one partner is HIV-1 infected and the other is uninfected) which was
established in Lusaka, Zambia, in 1994 to provide voluntary HIV-1 testing and
counseling, health care, and longitudinal monitoring for incident infections (1,
25). Although the number of new HIV-1 infections in this cohort has been less
than the number in the general population, seroconversion still occurs at a
frequency of 8.5 per 100 person years, with similar female-to-male and male-to-
female transmission rates (7). HIV-1-negative subjects were monitored for an-
tibody seroconversion at 3-month intervals, and all new infections were molec-
ularly characterized to determine whether they had resulted from transmission
by the cohabiting partner (“linked” transmission) or a different individual (“un-
linked” transmission) (47). Six of the 12 individuals included in the current study
had epidemiologically linked infections, while the other six had unlinked infec-
tions. Since the primary purpose of this study was to develop and validate a new
experimental strategy to infer transmitted HIV-1 env genes, no attempt was
made to match the demographic or laboratory characteristics of subjects with
linked or unlinked infections.
Laboratory staging of primary HIV-1 infection. The subjects were classified
according to the system of Fiebig et al. (8) that is based on the detection of
HIV-1-specific RNA, antigen, and antibody in plasma (Fig. 1). The Fiebig clas-
sification includes an eclipse phase that precedes the first detection of vRNA and
subsequent stages defined by the orderly appearance of viral markers: stage I
(vRNA positive, p24 antigen and antibody negative), stage II (vRNA and p24
antigen positive, antibody negative), stage III (enzyme-linked immunosorbent
assay [ELISA] antibody positive, Western blot negative), stage IV (ELISA pos-
itive, Western blot indeterminant), stage V (ELISA and Western blot positive,
p31 integrase antibody negative), and stage VI (ELISA, Western blot, and p31
integrase antibody positive). Plasma samples from the patients were tested for
HIV-1 antibodies by ELISA (Enzygnost HIV integral from Dade Behring, Mar-
burg, Germany; Biotest anti-HIV tetra ELISA from Biotest, Dreieich, Germany;
or Abbott Murex HIV Ag/Ab combination assay from Murex Biotech Limited,
Dartford, United Kingdom) and Western blot analysis (Genetics Systems HIV-1
Western blot from Bio-Rad Laboratories, Hercules, CA). In accordance with
diagnostic guidelines, a positive Western blot was defined as reactivity with any
two of the following three HIV-1 proteins: the exterior envelope glycoprotein/
uncleaved envelope precursor (gp120/gp160), the transmembrane envelope gly-
coprotein (gp41), and the major core protein (p24). An indeterminate Western
blot was defined as any visible band that did not meet the positivity criteria. A
negative Western blot included no visible bands. A subset of samples was also
monitored for p24 antigen by using a Beckman Coulter HIV-1 p24 antigen
ELISA (Beckman Coulter Inc., Fullerton, CA).
RNA extraction. For plasma specimens containing 10,000 RNA copies/ml,
plasma RNA was extracted by using a QIAamp viral RNA mini kit (Qiagen,
Valencia, CA). Samples with vRNA loads of 10,000 copies/ml were concen-
trated by centrifugation at 23,600  g for 1 h at 4°C prior to the same extraction
procedure. RNA was recovered from the spin columns in a final elution volume
of 50 l. For SGA and bulk PCR methods, between 1,000 and 20,000 vRNA
molecules were typically reverse transcribed.
cDNA synthesis. Reverse transcription of RNA to single-stranded cDNA was
performed by using the SuperScript III protocol according to the manufacturer’s
instructions (Invitrogen Life Technologies, Carlsbad, CA). RNA, deoxynucleo-
side triphosphates (0.5 mM each), and 0.25 M primer OFM19 (5-GCACTC
AAGGCAAGCTTTATTGAGGCTTA-3; nucleotides [nt] 9604 to 9632 of the
HXB2 sequence) were incubated for 5 min at 65°C to denature secondary
structure of the RNA. First-strand cDNA synthesis was carried out in 20- to
100-l reaction mixtures with 1 reverse transcriptase buffer containing 5 mM
dithiothreitol, 2 U/l of an RNase inhibitor (RNaseOUT), and 10 U/l Super-
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Script III. For SGA, the reaction mixture was incubated at 50°C for 60 min
followed by an additional hour at 55°C. For bulk PCR, the reaction mixture was
incubated at 55°C for 60 min. Following the completion of the reverse transcrip-
tion step, the reaction mixture was inactivated by being heated to 70°C for 15 min
followed by RNase H digestion at 37°C for 20 min (Invitrogen Life Technologies,
Carlsbad, CA). The resulting cDNA was used immediately for PCR or kept
frozen at 80°C until further analysis.
Standard (bulk) env gene amplification. Full-length rev/env cassettes (includ-
ing parts of the first exon of the tat gene; the entire vpu, rev, and env genes; and
parts of the nef gene) were amplified by nested PCR from plasma-derived viral
cDNA as previously described (5, 50, 51). Briefly, 1 l of bulk cDNA (containing
100 to 1,000 viral templates) was subjected to first-round PCR in a volume of 20
l. PCR was performed by using an Expand High Fidelity PCR system (Roche
Diagnostic Corporation, Indianapolis, IN) in 1 Expand PCR buffer containing
1.5 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate, and 0.2 M of
Vif1 (5-GGGTTTATTACAGGGACAGCAGAG-3; nt 4900 to 4923) and
OFM19 primers. The following cycling conditions were used: 94°C for 2 min
followed by 35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 4 min, with a
final extension of 68°C for 10 min. Second-round PCR was performed by using
1 l of the first-round PCR product and primers EnvA (5 GGCTTAGGCAT
CTCCTATGGCAGGAAGAA-3; nt 5954 to 5982) and EnvN (5-CTGCCAA
TCAGGGAAGTAGCCTTGTGT-3; nt 9145 to 9171) under the same condi-
tions used for the first-round PCR. To ensure that the amplified HIV-1 env
sequences were representative of the plasma quasispecies, five independent
nested PCRs were carried out for each specimen (20, 41). The final PCR prod-
ucts were analyzed by 1% agarose gel electrophoresis, and products of the
predicted size (3.2 kb) were ligated into the pcDNA3.1.V5-His TOPO TA
vector according to the manufacturer’s instructions (Invitrogen Life Technolo-
gies, Carlsbad, CA). The ligated vector was transformed into Stbl2 cells at 42°C
for 25 s (Invitrogen Life Technologies, Carlsbad, CA). Transformed reaction
mixtures were plated on LB-Amp (ampicillin; 100 g/ml) plates and cultured
overnight at 30°C. Multiple colonies were picked and grown in LB broth (100
g/ml ampicillin), and plasmid DNA was isolated by using a QIAprep spin
miniprep kit (Qiagen, Valencia, CA). The resulting plasmid DNA was subjected
to restriction enzyme digestion to identify full-length clones, and 10 to 37 env-
containing clones from each patient were sequenced.
SGA. For SGA of the full-length env genes, cDNA was endpoint diluted in
96-well plates such that fewer than 29 PCRs yielded an amplification product.
According to a Poisson distribution, the cDNA dilution that yields PCR products
in no more than 30% of wells contains one amplifiable cDNA template per
positive PCR more than 80% of the time. First-round PCR was carried out in 1
High Fidelity platinum PCR buffer, 2 mM MgSO4, 0.2 mM of each deoxynucleo-
side triphosphate, 0.2 M of primers Vif1 and OFM19, and 0.025 U/l platinum
Taq High Fidelity polymerase (Invitrogen, Carlsbad, CA) in a 20-l reaction
mixture. The PCR mixtures were set up in MicroAmp optical 96-well reaction
plates (Applied Biosystems, Foster City, CA) and sealed with ABI MicroAmp
adhesive film. The following PCR conditions were used: 94°C for 2 min followed
by 35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 4 min, with a final
extension of 68°C for 10 min. Second-round PCR was carried out using 1 to 2 l
of the first-round product and 0.2 M of primers EnvA and EnvN with the same
PCR mixture as the first round. The PCR conditions included: 94°C for 2 min
followed by 45 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 4 min, with a
FIG. 1. Laboratory staging of acute and early HIV-1 infections. (A) Temporal appearance of HIV-1-specific laboratory markers following
HIV-1 infection according to the classification system of Fiebig et al. (8). The eclipse phase is defined by the interval between transmission and
first detection of vRNA in the plasma and generally lasts about 10 days, with a range of approximately 7 to 21 days (3, 10, 17–19, 40). The mean
durations of Fiebig stages I (7 days), II (5 days), III (3 days), IV (6 days), and V/VI (70 days) are indicated. (B) Time points (x axis) at which
plasma samples were obtained for each of the 12 study subjects (y axis). Because subjects were studied at intervals of 3 months, the symbols are
positioned to represent the maximum possible number of days from transmission.
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final extension at 68°C for 10 min. The amplicons were sized on precast 1%
agarose E-gel 96 (Invitrogen Life Technologies, Carlsbad, CA). All products
derived from cDNA dilutions yielding less than 30% PCR positivity were se-
quenced. A standard operating procedure for SGA derivation of full-length env
genes is available upon request.
Generation of vRNA transcripts from HIV-1 molecular clones with T7 poly-
merase. Envelope genes corresponding to two transmitted strains of HIV-1
(BORId9.4F8 and BORId9.4F12) obtained from the plasma of an acutely in-
fected individual were directionally cloned into the viral expression vector
pcDNA3.1D (Invitrogen Life Technologies, Carlsbad, CA) under the control of
the T7 promoter. These plasmids were digested with EcoRV, and linear DNA
was recovered by QIAquick gel extraction (Qiagen, Valencia, CA) following
electrophoresis in 1% agarose. env RNA transcripts were generated using a
Riboprobe in vitro transcription system (Promega, Madison, WI) by incubating
700 ng template DNA with T7 polymerase at 37°C for 80 min and utilizing a
standard 100-l-volume transcription protocol under the following conditions:
1 optimized transcription buffer; 10 mM dithiothreitol; 0.5 mM rATP, rGTP,
rCTP, and rUTP; 100 U rRNasin RNase inhibitor; and 80 U T7 polymerase.
Following transcription, the DNA template was degraded with 1 U per g of
template RQ1 RNase-free DNase (Promega, Madison, WI) for 15 min at 37°C.
RNA molecules of more than 200 nucleotides were concentrated with RNeasy
MinElute cleanup (Qiagen, Valencia, CA) and stored at 80°C. The RNA’s
mass was determined by spectrophotometry (NanoDrop 1000), and the copy
number estimated assuming that all transcripts were full-length. RNA transcripts
(BORId9.4F8 and BORId9.4F12) were mixed 1:1 at an estimated 100,000 copies
total. RNA transcripts were reverse transcribed into cDNA (using primer
Env3in; see below) which was then diluted to the single-molecule level prior to
PCR amplification as described above, with the following primer modification:
for first-round PCR, primer Env5in (5-TTAGGCATCTCCTATGGCAGGAA
GAAG-3; nt 5957 to 5983) and antisense primer Env3in (5-GTCTCGAGAT
ACTGCTCCCACCC-3; nt 8904 to 8882) were used, and for second-round
PCR, primers 3R3BG (5-CCTATCTGTCCCCTCAGCTACTGC-3; nt 8510
to 8531) and 5F3BG (5-CGACGAAGACCTCCTCAAGACAG-3; nt 5993 to
6015) were used. A total of 59 envelope genes representing 145,590 bases were
sequenced and compared to the input env sequences to detect recombination
during cDNA synthesis and to identify all transversion, transition, and insertion-
deletion mutations.
Generation of virion RNA by transfection of 293T cells with HIV-1 molecular
clones. The infectious molecular clones YU2 and SG3 were independently trans-
fected into 293T cells (Fugene; Roche Diagnostic Corporation, Indianapolis, IN)
and cultured for 48 h to generate viral stocks. The virus concentration was
determined by using an Amplicor vRNA assay, version 1.5 (Roche Diagnostic
Corporation, Indianapolis, IN). Equal numbers of RNA molecules from each
virus stock were mixed 1:1, and 20,000 vRNA copies were extracted by using a
QIAamp viral RNA mini kit (Qiagen, Valencia, CA). Purified vRNA was reverse
transcribed into cDNA (using primer Env3out; see below) and diluted to the
single-molecule level prior to PCR amplification as described above, with the
following primer modifications: for first-round PCR, primer Env5out (5-TAG
AGCCCTGGAAGCATCCAGGAAG-3; nt 5853 to 5877) and antisense primer
Env3out (5-TTGCTACTTGTGATTGCTCCATGT-3; nt 8913 to 8936) were
used, and for second-round PCR, primer Env5in (5-TTAGGCATCTCCTATG
GCAGGAAGAAG-3; nt 5957 to 5983) and antisense primer Env3in (5-GTC
TCGAGATACTGCTCCCACCC-3; nt 8904 to 8882) were used. A total of 50
envelope genes representing 132,839 bases was sequenced and compared to the
input env sequences to detect recombination during cDNA synthesis and to
identify all transversion, transition, and insertion-deletion mutations.
DNA sequencing. Viral env genes were sequenced by using BigDye Terminator
chemistry and the protocols recommended by the manufacturer (Applied Bio-
systems, Foster City, CA). The sequences were determined by using an ABI
3730xl genetic analyzer (Applied Biosystems, Foster City, CA) and edited by
using the Sequencher program, version 4.7 (Gene Codes, Ann Arbor, MI). Both
strands of DNA were sequenced. All chromatograms were carefully inspected for
sites of ambiguous sequence (double peaks), and those that contained one or
more positions of mixed bases were excluded from further analysis.
Microsatellite analysis. Samples with heterogeneous infections were examined
for potential misidentification by microsatellite analysis using an AmpFlSTR
Identifiler PCR amplification kit following the manufacturer’s instructions (Ap-
plied Biosystems, Foster City, CA). Briefly, DNA was extracted from 200 l of
plasma by using a QIAamp DNA blood minikit (Qiagen, Valencia, CA) and used
for the amplification of 15 highly polymorphic microsatellite loci (D8S1179,
D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338,
D19S433, vWA, TPOX, D18S51, D5S818, and FGA) and a portion of the
amelogenin gene for gender identification in a single PCR amplification. The
amplicons were sized by using an ABI 3130 genetic analyzer. Data analysis and
allele designations were carried out by using the GeneMarker program (Soft-
Genetics LLC). The selected markers are widely accepted tetranucleotide loci
for genetic characterization, standardized under the Combined DNA Index
System (CODIS).
Phylogenetic analyses. Env protein sequences from each subject were aligned
using CLUSTAL W (46), and amino acids were then replaced by codons. In-
trastrain diversities were calculated by using uncorrected sequence distances. For
all other analyses, the alignments were gap stripped and sequences with large
deletions were excluded. All trees were constructed by using the neighbor joining
method (38) implemented in CLUSTAL W using Kimura’s correction (14). The
following subtype C sequences were included for reference: 98ZA502 (GenBank
accession no. AY158534), DU151 (GenBank accession no. DQ41185), DU422
(GenBank accession no. DQ411854), TV012 (GenBank accession no.
AF391243), TV002 (GenBank accession no. AF391232), SK144B1 (GenBank
accession no. AY703911), and BWMC168 (GenBank accession no. AF443087).
Recombination breakpoint analysis. Diversity plots were used to map break-
points in putative recombinants. The percent diversity between env nucleotide
sequences of a presumed recombinant and each of two parental strains believed
to have been involved in the recombination event was determined by moving a
window of 100 bp along an alignment in 10-bp increments. The distance values
for each of these pairwise comparisons were plotted at the midpoint of the
100-bp segment. Sites where the putative mosaic was equidistant from both
parents (i.e., sites where the two parental distance lines crossed) were scored as
recombination crossovers (due to the window size of 100 bp, the positions of
these breakpoints are only approximate). If the sequence distance between the
recombinant and both putative parents was greater than 0.05 (y axis), then this
sequence was scored as being of unknown origin. If the recombinant was iden-
tical to one putative parental sequence, then that sequence was taken to be the
parent, even if the nucleotide sequence distance in the window to the other
parent was less than 0.05. Finally, if the recombinant was identical to both
parents, no recombination breakpoint was invoked. All recombinants were con-
firmed by phylogenetic tree analysis.
Statistical analyses. Power calculations were performed to estimate the like-
lihood of missing infrequent viral variants present in patient plasma but not
sampled and represented in our env analyses. From probability theory, with n
plasma vRNA sequences, there is a 95% likelihood that a given missed variant
comprises a fraction f (or less) of the virus population where f 	 1  0.051/n. For
n 	 20, f is less than 14%; for n 	 30, f is less than 10%; and for n 	 40, f is less
than 8%.
We also estimated the probability that observed clusters of nonsynonymous
mutations in the Rev and Env coding regions could occur by chance; if the
estimated likelihood is small, we may infer that the clusters reflect selection of
variant amino acid sequences. We considered 9-codon windows because this was
the length of the observed clusters, and this is also the length of a typical T-cell
epitope. From the binomial expansion, the probability of seeing at least the
observed number (k) of clustered mutations within a single 9-mer is
r 
k 	 k
m
 mk pk
1 pm  k
where r is the number of potential 9-mers, m is the total number of mutations
relative to the consensus, and p is the probability that a mutation falls by chance
in any particular 9-mer. We calculated the probability only for k 	 k, since the
results for all k  k are very much smaller and can be ignored. Only nonsyn-
onymous mutations were included in the analysis. Within the 9-mers of interest,
but not elsewhere along the alignment, many of the mutations occurred in
multiple sequences. These multiple occurrences of the same mutation could
reflect common ancestry, although this is unlikely unless the mutations had
conferred a selective advantage; nevertheless, to be conservative, we considered
only distinct mutations in the analysis.
Nucleotide sequence accession numbers. The GenBank accession numbers for
all env sequences determined in this study are EU166353 to EU166402,
EU166413 to EU166473, EU166483 to EU166517, and EU166544 to EU166916,
except for one bulk-amplified sequence (DQ388514) which was reported previ-
ously.
RESULTS
Assay validation. The main objective of this study was to
develop and implement an experimental approach that would
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yield an accurate representation of the HIV-1 env genes in
plasma vRNA such that meaningful inferences concerning
their genetic (and ultimately, biological) properties could be
drawn. To this end, we first tested the performance of the
SGA-direct sequencing method using in vitro-generated
HIV-1 RNA templates. Two different approaches were used to
generate RNA templates from different sets of cloned HIV-1
DNA so as to account for (i) differences in fidelities between
T7 and human Pol II RNA polymerases and (ii) differences in
recombination rates between more- or less-related HIV-1
DNA templates. In the first set of experiments, we used T7
polymerase to synthesize vRNA from two HIV-1 env clones
derived from an acutely infected subject (BORI0637) in whom
we had observed extensive env gene recombination in vivo
(B. F. Keele, unpublished data). The two clones, BORId9.4F12
and BORId9.4F8, are 97.2% identical and represent the prog-
eny of two transmitted variants in this subject. From a 1:1
mixture of the two RNA genomes carried through cDNA syn-
thesis and SGA-direct sequencing, we obtained 59 full-length
env sequences, corresponding to 145,000 nucleotides. In none
of the sequences did we find evidence for recombination be-
tween the two genomes. The combined T7 polymerase and
Superscript III nucleotide misincorporation rate was 4.39 
104, consisting mainly of random nucleotide misincorpora-
tions (3.43  104) but also of single or double nucleotide
insertions or deletions in runs of common nucleotides (9.61 
105). Finally, transcripts from the two molecular clones were
recovered in equal proportions, demonstrating that heteroge-
neous templates are accurately represented using the SGA
approach (Table 1).
In a second set of experiments, we transfected 293T cells
with infectious molecular clones of HIV-1 (YU2 and SG3) and
collected virions from the culture supernatants for analysis.
This was done to avoid T7 polymerase contributions to the
measured error rate and to more closely replicate in vivo con-
ditions of HIV-1 gene expression and replication. The env
genes of YU2 and SG3 are 92.5% identical. Virion RNA
preparations from the two strains were mixed 1:1 and sub-
jected to cDNA synthesis and SGA-direct sequencing. Again,
the inspection of 50 env sequences corresponding to more than
132,000 nucleotides failed to yield evidence of recombination
but provided a nearly equal representation of both input
strains (Table 1). The combined error rate using RNA Pol II
and Superscript III was 8.28  105, consisting of random
nucleotide substitutions (6.77  105) and single-nucleotide
insertions or deletions in runs of A or T residues (1.51 105).
Of note, Taq polymerase misincorporations do not contribute
to this error rate because either they appear as mixed bases in
sequence chromatograms (if introduced during the first rounds
of amplification) and are thus discarded or they remain unde-
tected because they affect only a minor fraction of the ampli-
fied molecules. Thus, in addition to precluding artifactual re-
combination, SGA-derived sequences are not affected by Taq
polymerase-induced errors. These results, along with the rates
of transitions, transversions, insertions, and deletions, are sum-
marized in Table 1.
Laboratory staging of acute and early HIV-1 infection in
subjects. In order to evaluate the sequence diversity of HIV-1
in relation to the estimated duration of infection, we adopted
the Fiebig classification (8), which categorizes patients based
on an orderly and reproducible appearance of HIV-1-specific
markers in the plasma (Fig. 1A). The eclipse phase is defined
by the interval between virus transmission and the first detec-
tion of vRNA in the plasma and is believed to last on average
about 10 days, with a range of approximately 7 to 21 days (3,
10, 17–19, 40). The mean durations of Fiebig stages I (7 days),
II (5 days), III (3 days), IV (6 days), and V/VI (70 days) are
indicated. The 95% confidence intervals (CI) were calculated
and reported elsewhere (8). The timing of patient sampling
(Fig. 1B) was determined from the clinical record and by anal-
ysis of plasma vRNA, p24 antigen, and antibody, and all were
in good agreement (Table 2). Two subjects (ZM246F and
ZM247F) were initially studied during Fiebig stage II, when
their plasma vRNA levels were extremely high and HIV-1
antibody was undetectable. Subject ZM249M was first studied
during Fiebig stage IV, when plasma vRNA was still high and
antibodies were detectable by ELISA but the Western blot
pattern was indeterminant. Based on estimates of Fiebig stage
durations, this sample was still expected to have been obtained
within 31 days of infection. Subjects ZM246F, ZM247F, and
ZM249M were each studied at a second time point 4 to 80 days
after the first. The other nine subjects were studied on a single
TABLE 1. Determination of SGA-direct sequencing error rates using in vitro-synthesized HIV-1 RNA templates
Strain
No. (%) of:
Total no. of
errorsb (%)
Number of
recombinants (%)Genomes
sequenced
Genomes with
no errors
Nucleotides
sequenced Transitions Transversions Insertions
a Deletionsa
BORId9.4F12c 29 12 71,340 15 (0.0210) 7 (0.0098) 2 (0.0028) 3 (0.0042) 27 (0.038) 0 (1)
BORId9.4F8c 30 9 74,250 21 (0.0283) 7 (0.0094) 7 (0.0094) 2 (0.0027) 37 (0.050) 0 (1)
Total for both strains 59 21 145,590 36 (0.0247) 14 (0.0096) 9 (0.0062) 5 (0.0034) 64 (0.044) 0 (1)
YU2d 27 24 71,508 2 (0.0028) 0 1 (0.0014) 0 3 (0.0042) 0 (1)
SG3d 23 16 61,331 7 (0.0114) 0 0 1 (0.0016) 8 (0.013) 0 (1)
Total for both strains 50 40 132,839 9 (0.0068) 0 1 (0.0008) 1 (0.0008) 11 (0.0083) 0 (1)
a Insertion or deletion of 1 or 2 A or T nucleotides to a preexisting run of A or T residues.
b Total errors including transitions, transversions, insertions, and deletions.
c T7-generated HIV-1 RNA transcripts were mixed 1:1 and subjected to SGA analysis as described in the text.
d HIV-1 vRNA from transfected human 293T cell culture supernatants was mixed 1:1 and subjected to SGA analysis as described in the text.
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occasion no more than 99 to 151 days after infection, according
to their clinical records (Table 2).
env gene diversity in acute and early infections. A total of
417 SGA-derived full-length env gene sequences were obtained
from the 12 subjects, with a range of 24 to 49 sequences per
subject. A phylogenetic tree of these env sequences is shown in
Fig. 2. Eleven subjects were infected with HIV-1 subtype C;
one individual (ZM231F) harbored a strain that fell outside
FIG. 2. Env quasispecies complexity in 12 primary infection subjects from Zambia. A neighbor-joining tree of SGA-derived full-length env
sequences is shown. Brackets encompass sequences from each study subject, as indicated. Asterisks at nodes indicate 90% or higher bootstrap
values (shown only on branches whose length exceeds 0.003 substitutions per site). The scale bar represents 0.01 nucleotide substitutions per site.
98ZA502, DU151, DU422, TV012, TV002, SK144B1, and BWMC168 represent subtype C reference sequences. ZM231F falls outside all known
group M subtypes and thus remains unclassified.
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the established group M subtypes and thus remained unclas-
sified. The mean within-patient env nucleotide diversity ranged
from 0.05% to 4.26%, and the maximum within-patient env
nucleotide diversity ranged from 0.16% to 7.38% (Table 3).
Based on these values, the subjects could be divided into two
groups: those with maximum within-patient env diversities
greater than 1.0% (subjects ZM214M, ZM215F, ZM247F, and
ZM229M) and those with maximum within-patient env diver-
sities of less than 0.7% (the remaining eight subjects). We have
previously estimated that the maximum within-patient diversity
that can plausibly develop from a single infecting virus within
100 days is 0.60% (95% CI; range, 0.54 to 0.68%) and the
maximum within 150 days is 0.72% (95% CI; range, 0.65 to
0.85%) (B. F. Keele, unpublished data). Thus, the latter eight
subjects appeared to have been infected with a single viral
variant. To examine this further, we inspected the viral phy-
logenies more closely. As shown in Fig. 2, sequences from the
two subjects analyzed during the earliest stages of infection
(ZM246F and ZM249M) each formed single virus lineages
with very short branch lengths. The sequences from six other
subjects (ZM178F, ZM180M, ZM184F, ZM206F, ZM231F,
and ZM235F) also comprised discrete lineages, but with
slightly longer branches consistent with a longer duration of
infection, as indicated by their Fiebig stages (V and VI). The
other four individuals, including subject ZM247F, whose sam-
ple was obtained within 30 days of infection (Fig. 1B), exhib-
ited much greater diversities and had thus acquired more than
one virus strain.
To estimate the rate of env evolution in the critical period
spanning seroconversion, we examined sequences from one
individual (ZM246F) who had been infected by a single virus
(Fig. 2, Table 3) and from whom sequential blood samples
were obtained 80 days apart, during Fiebig stages II and VI
(Fig. 1B). First, a tree was constructed using the 27 sequences
from the earliest time point and was midpoint rooted. Second,
a tree was constructed using 41 sequences from both time
points and rooted to match the first tree, assuming a molecular
clock. The distance from the tip of each branch to the root of
the tree was calculated by using Branchlength (http://www.hiv
.lanl.gov/content/sequence/BRANCHLENGTH/branchlength
.html) and plotted against the time in days (0 days for
sequences from the 14 January 2003 time point and 80 days for
sequences from the 4 April 2003 time point). This yielded a
rate of evolution of 1.7  105 substitutions per site per day
(6  103 substitutions per site per year), which is very close to
a rate previously obtained for HIV-1 env gene sequences (16)
and similar to the mutation rate of HIV-1 in cell culture (2.4 
105 mutations per site per replication cycle, excluding
insertions and deletions), assuming a replication time between
1 and 2 days (23). To estimate the time to the most-recent
common ancestor (MRCA) for sequences from all 12 primary
infection subjects, this rate was applied to the average branch
length of their respective env sequences to the root of the tree.
For subjects ZM247F and ZM246F, from whom samples were
obtained very early (Fig. 1B), estimates of the time to the
MRCA of their transmitted viruses ranged between 10 and 31
days (Table 3), well within the upper bounds of the Fiebig
eclipse phase and stages I and II (note that this is true for each
of the two variants acquired by subject ZM247F). For subject
ZM249M, the same estimate was 31 days, which corresponds
to the approximate beginning date for Fiebig stage IV (Fig.
1B). For the other six subjects with homogeneous virus
populations, from whom samples were obtained no later
than 99 to 151 days postinfection according to clinical and
serological data, the env diversities implied a time to the
MRCA ranging from 43 to 73 days for stage V subjects and 73
to 112 days for stage VI subjects, again within the bounds of
the corresponding Fiebig stages. These findings supported the
conclusion that subjects ZM178F, ZM180M, ZM184F,
ZM206F, ZM231F, and ZM235F, like subjects ZM246F and
ZM249M, each had been infected by a single virus. Conversely,
subjects ZM214M, ZM215F, and ZM229M all had env
TABLE 3. Diversity of SGA-direct sequence-derived complete env genes in subjects with primary HIV-1 infections
Subject Fiebigstage
Date sample
collected
(mo/day/yr)
No. of
SGA env
amplicons
Nucleotide
sequence
length
Nucleotide
sequence diversity
Amino acid
sequence diversity
Time to
MRCAa
(days)
Viral complexity
No. of
variants
transmittedMean Range Mean Range
ZM184F V 07/10/03 26 2604–2621 0.13 0.00–0.31 0.33 0.00–0.80 43 Homogeneous 1
ZM214M VI 07/02/03 35 2544–2568 0.45 0.00–1.10 0.93 0.00–2.00 231 Heterogeneousb 1
ZM215F VI 10/19/02 32 2502–2580 4.26 0.00–7.38 7.32 0.00–13.4 1,869 Heterogeneous 4
ZM246F II 01/14/03 27 2532 0.05 0.00–0.20 0.10 0.00–0.36 26 Homogeneous 1
VI 04/04/03 14 2531–2532 0.31 0.16–0.40 0.58 0.24–0.95 107
ZM247F II 10/28/03 25 2583–2595 1.12 0.00–2.74 1.78 0.00–4.40 788c Heterogeneous 2
III 11/01/03 19 2592–2595 0.56 0.00–2.70 0.90 0.00–4.29 774
ZM249M IV 08/05/03 24 2562–2563 0.07 0.00–0.27 0.16 0.00–0.82 31 Homogeneous 1
V 08/12/03 25 2562 0.05 0.00–0.16 0.14 0.00–0.47 16
ZM178F VI 01/18/03 26 2560–2613 0.41 0.00–0.67 0.99 0.00–1.85 112 Homogeneous 1
ZM180M V 07/20/02 24 2588–2560 0.23 0.04–0.39 0.47 0.00–1.06 71 Homogeneous 1
ZM206F VI 07/13/02 35 2538–2560 0.25 0.04–0.47 0.61 0.00–1.29 73 Homogeneous 1
ZM229M VI 10/19/02 29 2526–2592 2.28 0.04–5.82 4.08 0.00–10.3 1,502 Heterogeneous 4
ZM231F V 12/17/02 48 2513–2545 0.13 0.00–0.43 0.32 0.00–1.30 73 Homogeneous 1
ZM235F V 12/20/02 28 2244–2565 0.16 0.00–0.39 0.34 0.00–0.82 54 Homogeneous 1
a The time to the MRCA was estimated by using the average branch length to root of midpoint-rooted neighbor-joining trees (inferred after excluding gaps and with
Kimura’s two-parameter correction) assuming a rate of 1.7  105 substitutions per site per day (estimated from the extent of env sequence divergence in subject
ZM246F).
b The number of transmitted variants could not be determined.
c The time to the MRCA for sequences within each of the two discrete transmitted virus lineages in subject ZM247F was estimated to be between 10 and 31 days.
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sequences whose diversities led to time estimates for an
MRCA virus that far exceeded plausible durations for a single
virus source given their Fiebig stage, and this was also true for
the two variants identified in subject ZM247F (Table 3). These
subjects had therefore clearly been infected by two or more
viral variants. Detailed recombination analysis of the viruses
from subjects ZM229M and ZM215F indicated at least four
different transmitted variants (see below), while the number of
transmitted variants for subject ZM214M could not be
determined with certainty (Table 3).
Identification of transmitted or early “founder” viruses. The
estimates of time to the MRCA for all subjects with homoge-
neous infections suggested that viral sequences were coalescing at
or near the transmission event. To evaluate this further, we se-
lected for analysis three subjects (ZM249M, ZM247F, and
ZM246F) from whom we had very early samples. Figure 3 depicts
the phylogenetic trees of the SGA-derived env sequences from
two consecutive plasma samples obtained from each of these
subjects 4 to 80 days apart. The sequences were also exam-
ined by using a novel analytical tool, Highlighter (http://www
.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html),
which provides a visually informative representation compar-
ing each env sequence to a selected reference sequence. For
subject ZM249M, both the phylogenetic tree and Highlighter
analysis identified a single set of 48 identical or nearly identical
sequences that differed from the consensus by 4 or fewer nu-
cleotide substitutions, while any 1 sequence differed from an-
other by a maximum of 8 nucleotides (0.3% maximum diver-
sity) (Fig. 3A). For subject ZM247F, both the phylogenetic
tree and Highlighter analysis identified two distinct sets of
identical or nearly identical env sequences. Although the se-
quences in one lineage differed from those in the other lineage
FIG. 3. Identification of transmitted or early founder env genes in subjects with acute HIV-1 infection. SGA-derived env sequences from pre-
and postseroconversion plasma samples from subjects ZM249M (A), ZM247F (B), and ZM246F (C) were examined by phylogenetic tree
construction (left panels) and Highlighter analysis (right panels). Sequences from the earlier time points are in bold face. Trees are midpoint
rooted. The scale bars represent 1 (A and C) or 10 (B) nt substitutions per site. The corresponding Highlighter diagrams denote the locations of
nucleotide sequence substitutions in each env sequence in comparison to a reference sequence listed at the top; the positions of these substitutions
within the env sequence are indicated at the bottom. Nucleotide substitutions and gaps are color coded. For each subject, sets of identical and
nearly identical env sequences form consensus sequences that coalesce to transmitted or early founder viral env sequences. Subjects ZM249M and
ZM246F were infected by a single virus and ZM247F by two viruses, identified as variant 1 and variant 2 in the tree (panel B). The tick in
parentheses in sequence 080503_A5 (panel A) indicates a single-nucleotide insertion. The boxed region in panel C indicates clustered mutations
in V3. Interestingly, these changes were limited to position 8 (Ile to Thr, Arg, or Lys) and position 25 (Asp to Asn, Glu, or Gly).
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by as many as 66 nucleotides (2.7% maximum diversity), the
sequences from within a lineage differed by no more than 4
nucleotides from each other and by no more than 2 nucleotides
from the lineage consensus (0.2% maximum diversity) (Fig.
3B). Finally, for subject ZM246F, a set of 26 identical or nearly
identical sequences that differed from the consensus by 3 or
fewer nucleotides and from each other by a maximum of 5
nucleotides (0.2% maximum diversity) was identified for the
first time point (Fig. 3C). Fourteen env sequences obtained 80
days later were still closely related to the original consensus
sequence, although none was identical to an earlier sequence.
Nonetheless, their consensus was still identical to the consen-
sus of the earlier time point. Mathematical models of virus
replication and diversification that assume exponential growth
in the absence of immune selection predict a high proportion
of identical sequences in acute and very early infections (B. F.
Keele, unpublished data). For subject ZM247F, lineages 1 and 2,
and subjects ZM246F and ZM249M, the proportions of identical
sequences in the earliest samples were 5/7 (71%), 11/18 (61%),
16/27 (59%), and 11/24 (45%), consistent with the model expec-
tations. Thus, we conclude that these consensus sequences corre-
spond to the transmitted or early “founder” viruses that initiated
productive clinical infection in these subjects.
env gene evolution postseroconversion. Although it is pref-
erable to collect sequential plasma samples before and after
seroconversion for the analysis of env evolution, this is not
always feasible, especially in large-scale natural history studies
or vaccine trials. We thus sought to determine what inferences
could be drawn concerning the transmitted virus and its early
evolution from the analysis of SGA-derived sequences from
later time points, without the benefit of earlier samples. Figure
4 illustrates two examples. Samples were obtained from subject
ZM180M during Fiebig stage V, no more than 124 days after
infection, and from subject ZM206F during Fiebig stage VI, no
more than 151 days after infection. Based on the extent of
maximum env diversity in these subjects (0.39% and 0.47%,
respectively) and on their env phylogenetic trees, we deter-
mined that each had likely been productively infected by a
single virus. Inspection of the Highlighter plot of sequences
from subject ZM180M provided evidence of strong selection in
the env region that overlaps the second exon of rev (Fig. 4A,
left panel). When compared to the consensus sequence, each
of 24 env/rev sequences contained a mutation within a region
spanning 24 nucleotides; one of the sequences contained two
mutations (Fig. 4A, middle panel). These 25 differences from
the consensus comprised seven different mutations, each
present in one to eight different sequences. All of these muta-
tions were nonsynonymous in the rev reading frame, yielding
seven different amino acid replacements within a single Rev
9-mer (Fig. 4A, right panel). We note that 9 amino acids is the
length of a typical T-cell epitope. Given that there were only
eight different mutations within the rev exon, we estimated the
probability that seven would fall within a single 9-mer as less
than 106. There was equally strong evidence of selection in
the sample from subject ZM206F, where each of 35 env se-
quences contained at least one mutation or a deletion within a
span of 9 codons (Fig. 4B, left panel). The 41 nucleotide
changes comprised 16 different mutations (Fig. 4B, middle
panel), all of which were nonsynonymous with respect to the
consensus sequence (Fig. 4B, right panel). Given that there
were 54 different nonsynonymous mutations within the env
gene, we estimated the probability that 16 would fall within a
single 9-mer as less than 1012 (these probability calculations
are conservative in that they assume that each of the observed
mutations arose only once and that the multiple occurrences of
some of the mutations reflect common ancestry).
Contribution of viral recombination to env gene diversity.
Recombination can accelerate virus evolution and adaptation
by reassortment of large sequence fragments (13, 33, 53). Sub-
jects ZM229M and ZM215F exhibited the greatest within-
patient env diversity, and we examined sequences from each
for evidence of recombination by using the SGA-direct se-
quencing approach. Both subjects had evidence of infection by
two or more viruses, based on their env diversity and estimates
of timing to the MRCA (Table 2). Sequences from both sub-
jects also contained numerous recombinants comprised of two
or more transmitted lineages. The majority of these recombi-
nants were likely generated in the newly infected individuals
and not in the transmitting partner, since most of the mosaic
sequences were unique and very closely related to only two
transmitted parental strains. For example, sequence C15 from
subject ZM229M contained seven putative recombination
crossover sites, but all fragments between these crossover
points were identical (or nearly identical) to those of one of the
two transmitted variants, C2 or D19 (Fig. 5B). Sequences D1
(Fig. 5C) and C10 (not shown) exhibited a similar pattern,
although they contained fewer crossover sites. Sequences D4
and D10 were very closely related to C15 (Fig. 5A) and shared
identical recombination breakpoints; this is most readily ex-
plained by assuming recombination in the newly infected sub-
ject followed by a clonal expansion of the mosaic virus. For
subject ZM215F, there was an even greater number of recom-
binants which were derived from the two major transmitted
variants (Fig. 5D). However, three mosaic sequences (D4, B8,
and F17) were of particular interest since they contained short
regions that were equally distant from the two principal lin-
eages, suggesting that these viruses had recombined with ad-
ditional viruses not represented in the phylogenetic tree (two
examples are shown in Fig. 5E and F). Based on these and
additional phylogenetic analyses (not shown), we estimated
that subjects ZM229M and ZM215F each had acquired at least
four different variants which had undergone extensive recom-
bination. Thus, recombination accelerates sequence diversifi-
cation in newly infected individuals.
Comparison of SGA and bulk amplification methods for
analyzing HIV-1 diversity. Because previous studies of viral
diversity in acute HIV-1 infection have generally utilized non-
SGA methods, we sought to compare the two strategies side-
by-side on the same clinical samples. Specifically, we asked
whether SGA and bulk PCR methods were equivalent in pro-
viding an accurate representation of virus identity and di-
versity. The results showed that this was not the case: bulk
amplification was prone to introducing a variety of method-
ological artifacts. Figure 6 depicts the phylogenies of 19 SGA-
derived (Fig. 6A) and 34 bulk-amplified env sequences (Fig.
6B), both obtained from the sample obtained on 1 November
2003 from subject ZM247F. What is immediately apparent is
that the terminal branches of the bulk-amplified env sequences
are consistently longer than those of SGA-derived sequences.
This is most obvious for the more abundant of the two trans-
3962 SALAZAR-GONZALEZ ET AL. J. VIROL.
FIG. 4. Evidence of immune selection in two subjects sampled at later Fiebig stages. (A) Highlighter analysis of SGA-derived env sequences
(left panel) from subject ZM180M (Fiebig stage VI), and corresponding nucleotide (middle panel) and amino acid (right panel) sequence
alignments from the overlapping rev gene. Boxes indicate mutations that cluster within a 27-nt region that corresponds to a 9-mer in the Rev
protein sequence. (B) Highlighter analysis of SGA-derived env sequences (left panel) from subject ZM206F (Fiebig stage VI), and corresponding
nucleotide (middle panel) and amino acid (right panel) sequence alignments of the V1 region. Boxes indicate mutations that cluster within a 27-nt
region that corresponds to a 9-mer of the V1 loop. In Highlighter analyses, nucleotide substitutions and gaps are color coded. The consensus
sequence is at the top of each alignment; lowercase letters show residues where mutations occurred. Dashes in the alignments indicate sequence
identity to the consensus; dots indicate deletions.
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FIG. 5. In vivo recombination in multiply-infected subjects. (A) Neighbor-joining tree of SGA-derived env sequences from subject ZM229M
depicting two major transmitted variants (orange and purple), as well as five in vivo-generated recombinants (black). Asterisks at nodes indicate
90% or higher bootstrap values. The scale bars represent 0.005 nucleotide substitutions per site. (B-C) Diversity plots of two representative
recombinants identified in panel A. The sequence distances of ZM229M_C15 (panel B) and ZM229M_D1 (panel C) are compared to those of
representatives of the two parental lineages (orange and purple, respectively). The two recombinants contain between one and seven crossovers;
schematic representations of their putative mosaic structures are shown below. (D) Neighbor-joining tree of SGA-derived env sequences from
subject ZM215F depicting two major transmitted variants (orange and purple), as well as 19 different recombinants (black). Asterisks and scale
bar are as described for panel A. (E-F) Diversity plots of two ZM215F recombinants containing “extraneous” sequences. The sequence distances
of ZM215F_D4 (panel B) and ZM215F_F17 (panel C) are compared to those of representatives of the two parental lineages (orange and purple,
respectively). Shaded areas indicate regions where ZM215F_D4 and ZM215F_F17 are equidistant from the two parental lineages, suggesting
recombination with additional variants. Schematic representations of their putative mosaic structures are shown below.
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mitted variants: in comparing 17 SGA-derived and 25 bulk-
derived env sequences to their corresponding consensus se-
quence, we found average distances of 0.028% (0.73
substitutions) and 0.094% (2.4 substitutions) for SGA- and
bulk PCR-derived sequences, respectively. This difference is
highly significant (t test; P  0.0001) and can be attributed to
Taq-induced misincorporations; such Taq-induced errors are
evident in sequences of individual env clones derived from bulk
PCR, but not in sequences of uncloned SGA amplicons since
they represent only a very minor population. Similar results
were obtained for the sample from a second subject (ZM249M)
when 25 SGA-derived and 12 bulk-derived sequences were com-
pared to their corresponding consensus env sequence (not
shown). The average distance of the SGA sequences was 0.027%
(0.7 substitutions), compared to 0.073% (1.9 substitutions) for the
bulk sequences. Again, these differences were statistically signif-
icant (P  0.002) and attributable to Taq-induced errors.
Bulk amplification also generated a surprisingly large num-
ber of recombinants compared to the SGA approach, where
none were evident. This is exemplified in Fig. 6B, showing the
results of bulk amplification of plasma from subject ZM247F
that yielded 8 recombinants out of 34 sequences (Fig. 6C and
D), as opposed to no recombinants out of 19 sequences derived
by SGA from the same sample. To insure that we had suffi-
ciently sampled the plasma virus pool by SGA, we obtained 25
additional SGA sequences from a second plasma sample col-
lected 4 days earlier. Again, no mosaic sequences were found
(Fig. 3B). Power calculations indicated that with a sample size
of 44 sequences, we could be 95% confident that any missed
variant (including a recombinant) comprised less than 7% of
the virus population. These data suggest that bulk PCR facil-
itates template switches by the Taq polymerase, generating
recombinants in vitro that do not exist in vivo.
Comparison of SGA and bulk amplification methods for
detection of specimen cross contamination. Quality control
and assurance are always a concern in large-scale clinical trials,
since specimens can be misidentified, cross-contaminated, or
otherwise compromised. In the course of the present study, we
obtained one plasma sample from subject ZM246F in which
phylogenetic analyses suggested specimen cross contamina-
tion. This questionable sample revealed three SGA-derived
env lineages (Fig. 7A), in contrast to the presence of a single
viral lineage in this individual’s plasma 3 months earlier (Fig.
3C). We considered the possibility that subject ZM246F had
become super-infected in the intervening 80 days, but the ex-
tent of sequence diversity within the blue lineages made this
explanation extremely unlikely. When bulk PCR was per-
formed on the questionable specimen (Fig. 7B), we obtained
an even more complicated phylogenetic tree, this time reveal-
ing three lineages plus two additional recombinant viruses
(ZM246F/M_BULK_41 and ZM246F/M_BULK_60). We re-
solved this quandary by reviewing clinic records and subjecting
FIG. 6. Bulk PCR-induced in vitro recombination in a multiply-infected individual. (A) Neighbor-joining tree of SGA-derived env sequences
derived from subject ZM247F (sample obtained 1 November 2003) depicting two major transmitted variants (green and blue; sequences of the
more-abundant variant are in green) and no recombinants. (B) Neighbor-joining tree of bulk PCR-derived env sequences amplified from the same
specimen depicting two transmitted variants (green and blue; sequences of the more-abundant variant are in green) and eight recombinants (red).
Asterisks at nodes indicate 90% or higher bootstrap values. The scale bars show 0.002 substitutions per site. (C and D) Diversity plots of two
representative recombinants in panel B. The two recombinants contain one or more crossovers, the approximate positions of which are indicated
by nucleotide position (x axis) and shown schematically below the panels.
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the questionable plasma sample to DNA microsatellite analy-
sis. The comparison of 15 polymorphic loci and one gender
marker revealed three rather than two alleles in the question-
able sample, but not in samples from three control subjects
with heterogeneous HIV-1 infections (Table 4). This finding
indicated that genetic material from two different individuals
had been mixed in the questionable ZM246F sample. Analysis
of peripheral blood mononuclear cell DNA from the partner
(ZM246M) of subject ZM246F provided an explanation: the
contaminating alleles in the questionable specimen were his
(Table 4). Thus, during the processing of the couple’s blood on
the 4 April 2003 clinic visit, the two plasma samples were
inadvertently mixed. This inadvertent sample contamination
was informative in that the two recombinant viruses whose
diversity plots are shown in Fig. 7C and D could only have been
generated in vitro as an artifact of Taq-induced template
switching, since the two viral lineages from which they were
derived never coexisted in the same individual. Moreover, a
substantial number of the bulk-derived (17 out of 25), but not
SGA-derived, sequences of ZM246M were identical or nearly
identical, most likely because of target resampling and/or dif-
ferences in cloning efficiency among different env sequences
(20).
DISCUSSION
The primary objective of this study was to develop, validate,
and implement a new experimental strategy for analyzing com-
plete HIV-1 env genes and, eventually, complete HIV-1 ge-
nomes from plasma RNA in a manner that would accurately
reflect their identity and composition in vivo. To this end, we
adapted methods previously described by other investigators
(27, 43–45) and tested them using in vitro-synthesized HIV-1
RNA transcripts of known sequence identity and plasma spec-
imens from subjects with acute and early infections. Using an
equal mixture of T7-synthesized RNA transcripts from two
related but distinct HIV-1 env clones (BORId9.4F12 and 4F8),
we carried out SGA-direct sequencing to estimate the rates of
nucleotide misincorporation and recombination from this
method. We observed 3.4 assay-related errors per 10,000 nu-
cleotides, indicating a misincorporation rate of 0.034%. In
addition, we observed a 0.01% rate of elongation errors within
runs of the same nucleotide. We attribute these rates to a
combination of T7 polymerase and Superscript III reverse
transcriptase errors and note that Palmer and coworkers re-
ported very similar values (0.011% nucleotide substitution er-
rors and 0.022% elongation errors) for T7 RNA transcripts of
FIG. 7. Bulk PCR-induced in vitro recombination in a mixture of two plasma samples. (A) Neighbor-joining tree of SGA-derived env sequences
derived from a mixture of plasma from two infected subjects, ZM246F (green) and ZM246M (blue). Subject ZM246M was chronically infected
with at least two major viral lineages (dark and light blue) that differed in their env sequences by approximately 6%. ZM246F was acutely infected
with a virus from an unrelated individual which differed from the ZM246M env sequences by approximately 10%. (B) Neighbor-joining tree of bulk
PCR-amplified env sequences from the same mixed-plasma specimen. In addition to viral lineages representing ZM246F (green) and ZM246M
(blue), two additional recombinants (ZM246F/M_BULK_41 and ZM246F/M_BULK_60) are apparent (red). Asterisks at nodes indicate 90%
or higher bootstrap values. The scale bars show 0.01 nucleotide substitutions per site. (C and D) Diversity plots of the two recombinants in
panel B. The approximate position of recombination crossovers is indicated by nucleotide position (x axis) and schematically shown below
the panels.
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HIV-1 pro-pol genes (27). We also performed SGA analysis on
an equal mixture of vRNA from two transfection-derived
HIV-1 strains, YU2 and SG3. Here, human RNA Pol II, and
not T7 polymerase, catalyzes the RNA synthesis step. In this
case, we observed a nucleotide misincorporation rate of
0.0068%, or 0.68 assay-related errors per 10,000 amplified nu-
cleotides. In addition, we observed a 0.0015% rate of elonga-
tion errors within runs of A or T residues. We attribute these
to a combination of human Pol II and Superscript III reverse
transcriptase errors and note that Mansky and Temin reported
a similar value of 0.0034% for the overall HIV-1 reverse tran-
scriptase-plus-human Pol II error rate on a lacZ template (23).
Thus, the total error rate of the SGA-direct sequencing
method as described here for the analysis of HIV-1 env se-
quences is no more than 8  105, due mostly to Superscript
III errors. This is not a negligible error rate even when Taq
polymerase errors are avoided altogether (by direct sequencing
of uncloned amplicons), since it can lead to single-nucleotide
misincorporations in as many as 1 in 5 env sequences. None-
theless, we suspect that 8  105 is an upper limit for the
Superscript III error rate in our analyses, since in some pa-
tients with very early infection (Fiebig stages I and II), we
found as many as 48 of 52 (92%) plasma virion env sequences
to be identical, with the remaining four varying by only five
nucleotides altogether; this yields an inferred rate of Super-
script III error of 4  105 (G. M. Shaw and B. H. Hahn,
unpublished data). For certain applications, such as identifying
transmitted or early founder sequences, infrequent nucleotide
misincorporations are of no consequence since many indepen-
dently generated sequences are analyzed together and all co-
alesce to a single consensus. However, if SGA-derived env
genes from chronically infected subjects, in whom most circu-
lating viruses are unique (27), are analyzed, then single-base-
pair misincorporations due to Superscript III error can be a
confounding variable. Finally, we examined whether cDNA
synthesis using Superscript III generated recombinant viral
sequences in vitro. Among 109 complete env sequences, cor-
responding to 278,000 nucleotides, we observed no recombi-
nants. We also observed no instances of intragenic recombina-
tion or of insertion, deletion, or duplication. Our findings are
thus in agreement with those of Palmer and coworkers, who
also found no evidence of Superscript III-mediated recombi-
nation, insertion, deletion, or duplication in any of 50 genomes
(66,000 nucleotides) analyzed (27). Although we did not for-
mally evaluate the substitution rates and template-switching
frequencies for Taq polymerase when using the bulk amplifi-
cation method, we frequently encountered Taq-induced re-
combinants and/or misincorporations in bulk-amplified se-
quences (Fig. 6 and 7). Moreover, in a separate study where we
obtained functional env clones from SGA-derived amplicons
(B. F. Keele, unpublished data), we identified (and discarded)
numerous clones that contained Taq-induced errors and thus
did not correspond to the env consensus sequences. These
clones were excluded from subsequent biological analyses
since they did not represent viruses present in the patient but
rather in vitro artifacts. We thus conclude that only SGA-based
strategies can unequivocally identify genetically linked muta-
tions and that assay-related nucleotide misincorporations and
recombination frequencies are much lower for SGA ap-
proaches than with other strategies.
A second objective of this study was to evaluate in a field
trial setting the ability of SGA-direct sequencing strategies to
decipher transmitted clade C (or other non-clade B) viruses
and their early evolution in a time frame typical of vaccine trial
follow-up schedules (every 3 months). In a companion study of
acute and early subtype B infections (B. F. Keele, unpublished
TABLE 4. Microsatellite analysis of plasma samples with heterogeneous viral sequencesa
Locus
Allele(s) identified in sample obtained (mo/day/yr) from indicated subject
ZM229M ZM215F ZM247F ZM246F ZM246Mc
04/04/0307/17/02 10/19/02 07/04/02 10/19/02 10/28/03 11/01/03 01/14/03 04/04/03b
D8S1179 14, 16 14, 16 13, 15 13, 15 15, 17 15, 17 14 14 14
D211S11 30.2, 31.2 30.2, 31.2 28, 36 28, 36 28.2, 27 28.2, 27 28, 31 27, 28, 31 27, 28
D7S820 11, 12 11, 12 8, 10 8, 10 10, 11 10, 11 10, 13 10, 12, 13 12
CSF1PO 7, 12 7, 12 10, 11 10, 11 10, 12 10, 12 7, 10 7, 10, 12 12
D3S1358 15, 17 15, 17 17 17 16, 17 16, 17 15 15, 16, 17 16, 17
TH01 6, 8 6, 8 7, 8 7, 8 7, 9.3 7, 9.3 7, 8 7, 8, 9 8, 9
D13S317 12, 13 12, 13 10,12 10, 12 12, 13 12, 13 11, 12 11, 12, 14 11, 14
D16S539 12, 13 12, 13 9, 12 9, 12 10 10 11 10, 11, 12 10, 12
D2S1338 22, 23 22, 23 21, 22 21, 22 20 20 19, 22 19, 22, 23 19, 23
D19S433 12, 14 12, 14 11, 13 11, 13 14, 16.2 14, 16.2 13, 14 13, 14, 15 13, 15
vWA 13, 20 13, 20 16, 17 16, 17 18 18 15 15 15
TPOX 9, 11 9, 11 10, 11 10, 11 9, 11 9, 11 7, 11 7, 8, 11 8, 11
D18S51 14.2, 16 14.2, 16 16, 18 16, 18 17, 20 17, 20 17, 18 16, 17, 18 16
D5S818 12 12 13 13 12, 14 12, 14 12, 13 11, 12, 13 11, 12
FGA 20, 22 20, 22 21, 26 21, 26 24, 28 24, 28 22, 23 22, 23 22, 23
Amelogenin Y Y X X X X X X, Y Y
a Microsatellite analyses were performed using DNA extracted from plasma samples, except for subject ZM246M for whom only peripheral blood mononuclear cell
DNA was available. Loci were amplified using an AmpFlSTR Identifiler kit (Applied Biosystems, Foster City, CA). This PCR amplification kit is a short tandem repeat
multiplex assay that amplifies 15 tetranucleotide repeat loci and the amelogenin gender-determining marker in a single PCR amplification; all identifiable alleles per
locus are shown.
b This sample was identified as an inadvertent mixture of plasma from two different individuals (ZM246F and ZM246M).
c Subject ZM246M is the chronically infected partner of subject ZM246F but not the individual who transmitted virus to subject ZM246F (see Fig. 7 and associated
text for explanation).
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data), we studied 51 subjects in Fiebig stages I/II and 26 sub-
jects in Fiebig stages III/IV; with such early sampling we found
that we could infer transmitted or early founder env sequences
in most patients, including those infected by more than one
virus. A mathematical model of early HIV-1 replication and
diversification described in that study provided the theoretical
basis for identifying transmitted or early founder viral ge-
nomes. Here, we were less certain whether this approach
would be applicable since the frequency of patient sampling
was less, samples were obtained from the majority of subjects
(9/12) weeks to months after infection (Fiebig stage V or VI),
and the genetic subtypes analyzed were non-clade B. Nonethe-
less, we show here for three subjects (ZM249M, ZM247F, and
ZM246F) studied prior to seroconversion that the phyloge-
netic trees and Highlighter analyses allow for an unambiguous
identification of the transmitted or early founder virus(es). For
six homogeneous-transmission cases studied later in the in-
fection process (ZM178F, ZM180M, ZM184F, ZM206F,
ZM231F, and ZM235), the env sequences also coalesced in a
time frame consistent with transmitted or early founder viruses
(Fig. 3, Table 3). However, this was not the case for individuals
who were infected by more than one virus and were sampled
for the first time at later time points (e.g., Fiebig stages V/VI);
in these instances, identification of the transmitted viruses was
precluded by more-extensive nucleotide substitutions, as well
as in vivo recombination. This limitation notwithstanding, our
findings for primary clade C infections mirror data obtained
for primary clade B infections (B. F. Keele, unpublished data):
sequences of transmitted or early founder env genes can be
readily inferred from SGA-derived sequences if subjects are
sampled sufficiently early (Fiebig stages I to IV) and, in some
cases, also at later time points (Fiebig stages V to VI) but only
if the infection was initiated by a single virus.
A third study objective was to determine if insights into
selection pressures on virus replication could be inferred from
SGA-derived sequences from single time points distant from
the transmission event. We show two examples of this. In Fig.
4A, the results of Highlighter analysis of 24 env sequences from
a subject at Fiebig stage V (ZM180M) are shown, illustrating
a heavy concentration of nucleotide substitutions in the region
of env that overlaps the second exon of rev. The actual nucle-
otide substitutions are shown in the middle panel. Each of the
24 sequences was found to contain one or more of seven
different mutations when compared to the consensus sequence.
Because of the large number of different mutations, it was
possible to infer the consensus sequence in this region and
across the entire env gene. Moreover, all of the nucleotide
substitutions concentrated within this 9-codon stretch of the
Rev open reading frame were nonsynonymous (Fig. 4A, right
panel). Statistical analysis ruled out the possibility that this
cluster of mutations arose by chance, and the observation most
likely reflects selection for sequences with amino acid differ-
ences. Although viably frozen lymphocytes were not available
for cytotoxic T-lymphocyte studies, this subject’s HLA pro-
file was typed as A*2901, A*3002, B*1510, B*4201,
Cw*0304, Cw*17(01-03). The Rev sequence under selection
pressure is LAEPVPLPLPPIERLNIGD, with the variable re-
gion underlined. There are several HLA-B42 and HLA-C mo-
tifs that overlap this region of interest, where potential second-
position and C-terminal anchor motifs are indicated as follows:
XPXXXXXXXXL (B*4201); XPXXXXXXL (B*4201); and
XAXXXXXXL (Cw*1701, Cw*1702, and Cw*0304). The po-
tential B*4201 epitopes are embedded directly in the region
that is the focus of the mutations, while the potential HLA-C
epitope is slightly offset. People who carry Cw*03 tend to have
a reaction to the peptide that spans this region more often than
people without Cw*03, suggesting that a Cw*03 epitope is
present and recognized in many subtype C infections (B. T.
Korber, unpublished data). A similar pattern of mutations in a
Rev 9-mer was recently identified in a subtype B-infected sub-
ject, and in this individual, HLA-restricted cytotoxic T-lympho-
cyte reactivity was confirmed by enzyme-linked immunospot
assay and gamma interferon induction (G. M. Shaw and P.
Borrow, unpublished data). In the sample from subject
ZM206, obtained in stage VI, there was equally strong evi-
dence of selection, again within a 9-amino-acid fragment but
this time within the variable loop 1 (V1) region of Env (Fig.
4B). Remarkably, 33 out of 35 sequences had 1 or more of 16
different point mutations within this region, while the other 2
sequences had deletions. This again allowed for the identifica-
tion of a consensus sequence that likely corresponds to the
transmitted or early founder sequence. Again, these changes
meant that every sequence sampled encoded a different amino
acid sequence when compared to the consensus, and again, the
likelihood of such a concentration of mutations occurring by
chance was estimated to be extremely low. The HLA profile of
this subject was A*0202, A*2301; B*1510, B*180101;
Cw*0501, Cw*1601, and the region of extreme selection is
GSSKANDNNVNITSD. There are no obvious anchor motifs
for the relevant HLAs in this sequence, although KANDN
NVNI could fit an A*0202 binding pocket (P. Goulder, per-
sonal communication). Alternatively, the observed cluster of
V1 mutations could be the result of neutralizing-antibody es-
cape (34). Taken together, these results indicate that molecu-
lar patterns of virus adaptation can be inferred even in samples
obtained several months after transmission from subjects for
whom earlier specimens are not available for comparison.
The SGA-direct sequencing approach is ideally suited to the
evaluation of genetic linkages, as described by Palmer et al. for
the analysis of drug resistance mutations in the pro-pol genes
(27). We sought to determine if SGA-direct sequencing might
reveal env gene recombination in subjects acutely infected by
more than one virus and then to compare recombination fre-
quencies between SGA and bulk amplification methods. Fig-
ure 5 illustrates multiple examples of viral recombination in
the two subjects at Fiebig stage VI, ZM229M and ZM215F.
Interestingly, in subject ZM215F, the recombination involved
not only two principal transmitted virus lineages but also ad-
ditional sequences not otherwise represented in the sequence
set. Exhaustive phylogenetic analyses indicated that subjects
ZM215F and ZM229M had each been infected by four or
more viruses (Table 3). Thus, in these two heterogeneous in-
fections, viral diversification was accelerated by extensive re-
combination.
Although viral recombination assessed by SGA methods can
be complicated and nearly indecipherable in multiply-infected
individuals at later time points, this problem is magnified if
bulk PCR methods are used. In Fig. 6, we show results for a
subject at Fiebig stage II who was infected by two variants. The
analysis of a total of 44 SGA-derived env sequences reveals no
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evidence of recombination, but 8 of 34 bulk PCR-derived se-
quences are mosaic, each exhibiting different breakpoint pat-
terns. Artifactual Taq-mediated template switching was also
demonstrated in an example of a cross-contaminated plasma
specimen from two subjects (ZM246F and ZM246M) who
were infected by unrelated viruses (Fig. 7). In the contami-
nated specimen, the SGA method clearly distinguished a single
ZM246F lineage from two ZM246M lineages with no recom-
binant viruses among them. Conversely, the bulk method gen-
erated two mosaic sequences in vitro that did not exist in vivo.
From the results of our analyses and those of other reports (27,
43–45, 54), we conclude that SGA methods do not generate in
vitro recombinants, whereas bulk methods commonly do. Bulk
amplification-cloning-sequencing strategies are also suscepti-
ble to Taq-induced nucleotide misincorporation, template re-
sampling, and cloning bias. These limitations may not be prob-
lematic for certain applications. However, if a goal is to obtain
sequences of appreciable length that correspond to HIV-1
genomes that exist in vivo, then SGA-direct sequencing ap-
proaches have distinct advantages.
The results of the present study, together with those of
Palmer et al. (27) and B. F. Keele (unpublished), illustrate new
scientific avenues for deciphering HIV-1 transmission and pat-
terns of early virus diversification. Based on the data reported
here, it is likely that these new approaches will help to clarify
the genetic and biological complexity of viruses transmitted by
different routes and under various clinical circumstances, all
factors that may be important in the design and assessment of
candidate vaccines, antiretroviral drugs, or microbicides. In
samples from clinical trial participants, it may be possible to
use SGA-based methods to generate not only transmitted and
evolved env genes but all HIV-1 genes of interest. Recently, we
have shown for seven clade B- or C-infected subjects that
complete (9 kb) HIV-1 genomes corresponding to the trans-
mitted or early founder virus can be identified by SGA-direct
sequencing methods (39). Such approaches may be useful in
mapping linked mutations conferring escape from cellular and
humoral immune responses in naı¨ve or vaccinated individuals.
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